AstraZeneca on Thursday said data from a trial it conducted on it COVID-19 shot Vaxzevria showed higher response of antibodies against omicron and other variants, when a third booster shot is given.
The company said the increased response was seen in people who were previously vaccinated with either Vaxzevira or an mRNA vaccine. It noted data would be submitted to regulators globally.
AstraZeneca has developed the vaccine with researchers from the University of Oxford, and lab studies last month found a three-dose course of Vaxzevria was effective against the rapidly spreading new variant.
